SEARCH

SEARCH BY CITATION

References

  • 1
    Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003;3:66675.
  • 2
    Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006;6:38393.
  • 3
    Sivendran S, Glodny B, Pan M, Merad M, Saenger Y. Melanoma immunotherapy. Mt Sinai J Med 2010;77:62042.
  • 4
    Hu ZW, Yang HZ. The pattern recognition receptor-mediated immune tolerance is involved in tumor metastasis. Sheng Li Ke Xue Jin Zhan 2010;41:510.
  • 5
    Motoyoshi Y, Kaminoda K, Saitoh O et al. Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. Oncol Rep 2006;16:1416.
  • 6
    Li J, Qian CN, Zeng YX. Regulatory T cells and EBV associated malignancies. Int Immunopharmacol 2009;9:5902.
  • 7
    Golovina TN, Vonderheide RH. Regulatory T cells: overcoming suppression of T-cell immunity. Cancer J 2010;16:3427.
  • 8
    Nakagawa Y, Watari E, Shimizu M, Takahashi H. One-step simple assay to determine antigen-specific cytotoxic activities by single-color flow cytometry. Biomed Res 2011;32:15966.
  • 9
    Schnurr M, Galambos P, Scholz C et al. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. Cancer Res 2001;61:644550.
  • 10
    Silke G, Michael S, Herbert R. Dendritic cells pulsed with tumor-derived lysateaugment T cell mediated tumor cell lysis. Otolaryngol Head Neck Surg 2004;131:1767.
  • 11
    Herr W, Ranieri E, OIson W et al. Mature dendritic ceIIs puIsed with freeze-thaw ceII Iysates define an effective in vitro vaccine designed to EBV-specific CD4+ and CD8+ T Iymphocyte eIicit responses. Blood 2000;96:185764.
  • 12
    Zhao WX, Yang JL, Li X, Ai J, Li T, Wang L. The quantitative detection of NKG2D, perforin and granzyme B gene expressions in lymphocytes by SYBR green I real-time fluorescence quantitative PCR. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2010;26:110810.
  • 13
    Li YY, Yan CL. Inhibition of elicitation of allergic contact dermatitis by topical use of Z-VAD-FMK, a broad caspase inhibitor: experiment in mice. Zhonghua Yi Xue Za Zhi 2012;92:19926.
  • 14
    Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008;3:11018.
  • 15
    Kawakami Y. Cancer treatment by comprehensive regulation of anti-tumor immune network. Nihon Rinsho 2010;68:10949.
  • 16
    Labarriere N, Khammari A, Lang F, Dreno B. Is antigen specificity the key to efficient adoptive T-cell therapy? Immunotherapy 2011;3:495505.
  • 17
    Jakóbisiak M, Gołab J. Genetic modification of T cells improves the effectiveness of adoptive tumor immunotherapy. Arch Immunol Ther Exp (Warsz) 2010;58:34754.
  • 18
    Liu JP, Chen W, Schwarer AP, Li H. Telomerase in cancer immunotherapy. Biochim Biophys Acta 2010;1805:3542.
  • 19
    Askenasy N, Kaminitz A, Yarkoni S. Mechanisms of T regulatory cell function. Autoimmun Rev 2008;7:3705.
  • 20
    Bianchini R, Bistoni O, Alunno A et al. CD4(+) CD25(low) GITR(+) cells: a novel human CD4(+) T-cell population with regulatory activity. Eur J Immunol 2011;41:226978.
  • 21
    Hazelrigg MR, Hirsch JI. Merchant RE. Distribution of adoptively transferred, tumor-sensitized lymphocytes in the glioma-bearing rat. J Neurooncol 2002;60:14350.
  • 22
    Skitzki J, Craig RA, Okuyama R et al. Donor cell cycling, trafficking, and accumulation during adoptive immunotherapy for murine lung metastases. Cancer Res 2004;64:218391.
  • 23
    Wu ZY, DU XH, Xu YX et al.Evaluation of in vivo labeled cytotoxic T lymphocytes and cytokine-induced killer cells migration and distribution of subcutaneous gastric tumor model in nude mice. Zhonghua Yi Xue Za Zhi 2010;90:4036.
  • 24
    Ridolfi R, Riccobon A, Galassi R et al. Evaluation of in vivo labelled dendritic cell migration in cancer patients. J Transl Med 2004;2:27.
  • 25
    Cullen SP, Brunet M, Martin SJ. Granzymes in cancer and immunity. Cell Death Differ 2010;17:61623.
  • 26
    Hassin D, Garber OG, Meiraz A, Schiffenbauer YS, Berke G. Cytotoxic T lymphocyte Perf and Fas ligand working in concert even when Fas ligand lytic action is still not detectable. Immunology 2011;133:1906.
  • 27
    Kim JH, Kang TH, Noh KH et al. Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8(+) T cell-mediated cell death. Immunol Lett 2009;122:5867.
  • 28
    Jenkins MR, Mintern J, La Gruta NL, Kedzierska K, Doherty PC, Turner SJ. Cell cycle-related acquisition of cytotoxic mediators defines the progressive differentiation to effector status for virus-specific CD8+ T cells. J Immunol 2008;181:381822.
  • 29
    Meslin F, Thiery J, Richon C, Jalil A, Chouaib S. GRZB-induced cell death involves induction of p53 tumor suppressor gene and its activation in tumor target cells. J Biol Chem 2007;282:329919.
  • 30
    Hershkovitz L, Schachter J, Treves AJ, Besser MJ. Focus on adoptive T Cell transfer trials in melanoma. Clin Dev Immunol 2010;2010:2607.
  • 31
    Ramakrishnan R, Assudani D, Nagaraj S et al. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest 2010;120:111124.